An advocate general at the Court of Justice of the European Union (CJEU) has issued a legal opinion stating that the European Commission failed to provide sufficient public access to redacted versions of its COVID-19 vaccine procurement contracts. The opinion, released in the ongoing legal battle regarding transparency in the purchase of billions of vaccine doses, suggests that the Commission’s restrictive approach to disclosing these documents did not adequately justify the protection of commercial interests.
The non-binding opinion, delivered by Advocate General Tamara Ćapeta, addresses a challenge brought by a group of Members of the European Parliament (MEPs) and other private individuals. The plaintiffs have long argued that the executive branch of the European Union should be held to higher standards of transparency given the massive scale of public funding involved in the procurement process. According to the official press release from the Court of Justice, the Advocate General concluded that the Commission’s decision to redact specific clauses—such as those concerning price, liability, and the location of manufacturing sites—was not sufficiently reasoned to withstand scrutiny under EU transparency regulations.
Legal Basis for Transparency in Procurement
At the heart of the dispute is the application of Regulation (EC) No 1049/2001, which governs public access to European Parliament, Council, and Commission documents. While the Commission initially argued that releasing the full contracts would jeopardize sensitive commercial negotiations and the intellectual property rights of pharmaceutical manufacturers, the Advocate General’s opinion highlights a fundamental tension between corporate confidentiality and the public’s right to know how taxpayers’ money is spent.
The Advocate General noted that the Commission failed to show how the disclosure of certain redacted parts would have specifically harmed the commercial interests of the companies involved. In her legal assessment, she emphasized that the Commission must provide a more rigorous explanation for every redaction applied to a public document. While the Court of Justice is not legally bound to follow the Advocate General’s opinion in its final ruling, the court typically aligns with these findings in a significant majority of cases. A final judgment from the Court is expected in the coming months, which could set a major precedent for future EU procurement transparency.
The Scope of Vaccine Contracts and Public Scrutiny
The procurement contracts in question relate to the massive orders placed by the European Commission during the peak of the pandemic. As documented by the European Parliament, MEPs have repeatedly questioned the terms negotiated with pharmaceutical giants, particularly regarding advance purchase agreements. The lack of transparency has led to persistent criticism from civil society groups and auditors, who argue that the secrecy surrounding the price per dose and indemnity clauses remains a point of contention.
The European Court of Auditors previously reported that while the Commission had successfully secured a diverse portfolio of vaccines, the negotiation process was characterized by a lack of clarity regarding the final contractual obligations. The ongoing legal case represents the latest step in a years-long effort to force the Commission to release unredacted versions of these agreements. For the public and health policy experts, the core issue remains the accountability of the EU institutions when they act as the primary purchaser for 27 member states.
What Happens Next?
The case now moves toward a final decision by the judges at the European Court of Justice. Once the Court issues its ruling, the European Commission will be required to align its disclosure policies with the judicial interpretation of EU transparency law. If the Court supports the Advocate General’s view, the Commission may be forced to release significantly more information regarding the specific terms of the vaccine deals, including details previously shielded by claims of commercial confidentiality.
For researchers and the public, this ruling will likely serve as a benchmark for how the Commission manages sensitive data in future health emergencies. Readers interested in following the final verdict can monitor the official Curia database for case updates and the eventual publication of the final judgment. We invite our readers to share their thoughts on the balance between state-level procurement confidentiality and the public’s right to information in the comments section below.
Related reading